About   Help   FAQ
Mammalian Phenotype Ontology Annotations
Query Results - Summary
Symbol
Name
ID
Cebpb
CCAAT/enhancer binding protein (C/EBP), beta
MGI:88373
145 phenotypes from 13 alleles in 18 genetic backgrounds
Export: Excel File
Allelic Composition
Genetic Background
Annotated Term Reference
Cebpbtm1.1Acle/Cebpb+
involves: 129P2/OlaHsd * BALB/c * C57BL/6
abnormal skeleton morphology J:150006
Cebpbtm1.1Acle/Cebpbtm1.1Acle
involves: 129P2/OlaHsd * BALB/c * C57BL/6
abnormal bone trabecula morphology J:150006
abnormal osteoblast physiology J:150006
abnormal osteoclast differentiation J:150006
abnormal osteoclast morphology J:150006
abnormal osteoclast physiology J:150006
enhanced osteoblast differentiation J:150006
increased bone mineralization J:150006
increased bone ossification J:150006
increased bone resorption J:150006
increased bone trabecula number J:150006
increased bone volume J:150006
prenatal lethality, incomplete penetrance J:150006
Cebpbtm1.1Elgaz/Cebpbtm1.1Elgaz
Lyz2em1.1Elgaz/Lyz2+
BALB/cJ-Cebpbtm1.1Elgaz Lyz2em1.1Elgaz
abnormal myeloid cell number J:247885
decreased circulating interleukin-10 level J:247885
decreased susceptibility to bacterial infection J:247885
decreased susceptibility to bacterial infection induced morbidity/mortality J:247885
decreased transforming growth factor level J:247885
increased circulating interleukin-6 level J:247885
increased circulating tumor necrosis factor level J:247885
Cebpbtm1.1Maka/Cebpbtm1.1Maka
Tg(Ins2-cre)23Herr/0
involves: 129P2/OlaHsd * C57BL/6J * CBA/J
normal homeostasis/metabolism phenotype J:156725
increased insulin secretion J:156725
Cebpbtm1Aki/Cebpbtm1Aki
involves: 129P2/OlaHsd * C57BL/6
abnormal macrophage physiology J:153025
abnormal T-helper 1 physiology J:153025
decreased susceptibility to endotoxin shock J:153025
granulomatous inflammation J:153025
increased susceptibility to bacterial infection J:153025
Cebpbtm1Es/Cebpbtm1Es
Tg(KRT5-cre)5132Jlj/?
involves: 129S1 * C57BL/6J * DBA/2J
decreased incidence of tumors by chemical induction J:107334
increased keratinocyte apoptosis J:107334
Cebpbtm1Es/Cebpbtm1Es
Tg(KRT14-cre/ERT)20Efu/0
involves: 129S1/Sv * C57BL/6 * CD-1
abnormal keratinocyte differentiation J:158721
epidermal hyperplasia J:158721
increased keratinocyte proliferation J:158721
normal integument phenotype J:158721
thick epidermis J:158721
Cebpbtm1Kish/Cebpb+
involves: 129P2/OlaHsd
abnormal skeletal muscle mass J:237461
Cebpbtm1Kish/Cebpbtm1Kish
involves: 129P2/OlaHsd
abnormal brown adipose tissue morphology J:45062
abnormal cell differentiation J:45062
abnormal clavicle morphology J:237461
abnormal macrophage physiology J:77003
abnormal thoracic cage morphology J:237461
abnormal zygomatic arch morphology J:237461
female infertility J:45062
impaired macrophage phagocytosis J:77003
increased interleukin-12 secretion J:126085
increased susceptibility to bacterial infection J:77003
neonatal lethality, incomplete penetrance J:45062
perinatal lethality, incomplete penetrance J:77003
postnatal lethality, incomplete penetrance J:45062, J:77003
Cebpbtm1Nerl/Cebpbtm1Nerl
Tg(Ckmm-cre)5Khn/0
involves: 129P2/OlaHsd * C57BL/6 * FVB
normal homeostasis/metabolism phenotype J:153686
normal muscle phenotype J:153686
Cebpbtm1Pfj/Cebpb+
B6.Cg-Cebpbtm1Pfj
decreased incidence of tumors by chemical induction J:73558
Cebpbtm1Pfj/Cebpbtm1Pfj
B6.Cg-Cebpbtm1Pfj
decreased incidence of induced tumors J:73558
decreased incidence of tumors by chemical induction J:73558
increased keratinocyte apoptosis J:73558
Cebpbtm1Pfj/Cebpbtm1Pfj
either: 129S1/SvImJ-Cebpbtm1Pfj or (involves: 129S1/SvImJ * C57BL/6)
abnormal branching of the mammary ductal tree J:48514
abnormal lactation J:48514
abnormal mammary gland development J:48514
Cebpbtm1Pfj/Cebpbtm1Pfj
involves: 129S1/Sv * C57BL/6
abnormal osteoblast physiology J:150006
abnormal osteoclast differentiation J:150006
abnormal osteoclast morphology J:150006
abnormal osteoclast physiology J:150006
abnormal skeleton morphology J:150006
abnormal tumor necrosis factor level J:192313
absent corpus luteum J:43075
absent estrous cycle J:43075
decreased bone mineralization J:150006
decreased bone ossification J:150006
decreased bone trabecula number J:150006
decreased bone volume J:150006
decreased ovulation rate J:43075
decreased trabecular bone thickness J:150006
female infertility J:43075
impaired granulosa cell differentiation J:43075
impaired luteinization J:43075
impaired ovarian folliculogenesis J:43075
increased bone resorption J:150006
prenatal lethality, incomplete penetrance J:43075, J:150006
normal reproductive system phenotype J:43075
Cebpbtm1Vpo/Cebpb+
involves: 129S/SvEv * C57BL/6 * MF1
abnormal mammary gland duct morphology J:48513
Cebpbtm1Vpo/Cebpbtm1Vpo
FVB.129S-Cebpbtm1Vpo
decreased sensitivity to induced cell death J:52729
Cebpbtm1Vpo/Cebpbtm1Vpo
involves: 129S/SvEv * C57BL/6
abnormal brown adipose tissue physiology J:117502
decreased body weight J:117502
decreased brown adipose tissue amount J:117502
decreased epididymal fat pad weight J:117502
decreased lipoprotein lipase activity J:117502
decreased triglyceride level J:117502
impaired adaptive thermogenesis J:117502
increased circulating glucose level J:117502
increased circulating triglyceride level J:117502
Cebpbtm1Vpo/Cebpbtm1Vpo
involves: 129S/SvEv * C57BL/6 * MF1
abnormal branching of the mammary ductal tree J:48513
abnormal gluconeogenesis J:49673
abnormal glucose homeostasis J:49673
abnormal mammary gland development J:48513
abnormal mammary gland duct morphology J:48513
abnormal mammary gland epithelium physiology J:48513
decreased liver regeneration J:49673
female infertility J:48513
hypoglycemia J:49673
Cebpbtm1Vpo/Cebpbtm1Vpo
involves: 129S/SvEv * MF1
abnormal adipose tissue physiology J:52286
abnormal cell-mediated immunity J:25215
abnormal circulating free fatty acids level J:52286
abnormal definitive hematopoiesis J:25215
abnormal enzyme/coenzyme level J:52286
abnormal gluconeogenesis J:52286
abnormal glucose homeostasis J:52286, J:62132
abnormal humoral immune response J:25215
abnormal innate immunity J:25215
abnormal lipid homeostasis J:52286, J:62132
abnormal lymph node B cell domain morphology J:25215
abnormal lymph node cortex morphology J:25215
abnormal lymph node medulla morphology J:25215
abnormal lymph node medullary cord morphology J:25215
abnormal lymph node secondary follicle morphology J:25215
abnormal lymph node T cell domain morphology J:25215
abnormal macrophage physiology J:25215
abnormal mucosa-associated lymphoid tissue morphology J:25215
abnormal plasma cell morphology J:25215
abnormal spleen red pulp morphology J:25215
abnormal spleen secondary B follicle morphology J:25215
abnormal spleen white pulp morphology J:25215
abnormal T-helper 1 physiology J:25215
abnormal T-helper 2 physiology J:25215
decreased circulating free fatty acid level J:52286, J:62132
decreased circulating insulin level J:62132
decreased circulating interleukin-12 level J:25215
decreased circulating leptin level J:62132
decreased circulating triglyceride level J:52286
decreased glycogen catabolism rate J:52286
decreased gonadal fat pad weight J:62132
decreased percent body fat/body weight J:62132
decreased susceptibility to type IV hypersensitivity reaction J:25215
decreased uterine fat pad weight J:52286
enlarged axillary lymph nodes J:25215
enlarged inguinal lymph nodes J:25215
enlarged lymph nodes J:25215
enlarged mesenteric lymph nodes J:25215
enlarged spleen J:25215
enlarged submandibular lymph nodes J:25215
expanded mesangial matrix J:25215
extramedullary hematopoiesis J:25215
glomerulonephritis J:25215
hemosiderosis J:25215
hypoglycemia J:52286, J:62132
impaired lipolysis J:62132
increased bone marrow cell number J:25215
increased circulating corticosterone level J:52286
increased circulating interleukin-6 level J:25215
increased IgG level J:25215
increased insulin sensitivity J:62132
increased muscle cell glucose uptake J:62132
increased susceptibility to fungal infection J:25215
mesangial cell hyperplasia J:25215
postnatal lethality, incomplete penetrance J:25215
premature death J:25215
renal glomerulus hypertrophy J:25215
skin lesions J:25215
Cebpbtm2.1Acle/Cebpbtm2.1Acle
involves: 129P2/OlaHsd * BALB/cJ * C57BL/6
abnormal osteoclast morphology J:155795
decreased cell proliferation J:155795
decreased liver regeneration J:155795
decreased osteoclast cell number J:155795
increased bone volume J:155795
increased circulating interleukin-6 level J:155795
increased trabecular bone thickness J:155795
normal reproductive system phenotype J:155795
Cebpbtm3.1Acle/Cebpbtm3.1Acle
involves: 129P2/OlaHsd * BALB/cJ * C57BL/6
no abnormal phenotype detected J:155795
Cebpbtm3Nerl/Cebpbtm3Nerl
either: B6.129P2-Cebpbtm3Nerl or (involves: 129P2/OlaHsd * C57BL/6)
calcified muscle J:153686
decreased skeletal muscle fiber size J:153686
impaired skeletal muscle regeneration J:153686
increased physiological sensitivity to xenobiotic J:153686
myositis J:153686
normal reproductive system phenotype J:153686
skeletal muscle fibrosis J:153686
Tg(Ins2-Cebpb)2Maka/0
involves: C57BL/6
abnormal pancreas physiology J:156725
decreased circulating insulin level J:156725
decreased insulin secretion J:156725
decreased pancreatic beta cell mass J:156725
increased circulating glucose level J:156725
increased pancreatic islet cell apoptosis J:156725

Contributing Projects:
Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Models of Human Cancer database (MMHCdb) (formerly Mouse Tumor Biology (MTB), Gene Ontology (GO)
Citing These Resources
Funding Information
Warranty Disclaimer & Copyright Notice
Send questions and comments to User Support.
last database update
08/13/2019
MGI 6.14
The Jackson Laboratory